LSL Pharma Group Inc.
LSL.V
TSX
09/30/2024 | 06/30/2024 | ||||
---|---|---|---|---|---|
Revenue | -4.03% | -0.81% | |||
Total Other Revenue | -- | -- | |||
Total Revenue | -4.03% | -0.81% | |||
Cost of Revenue | 6.37% | -13.29% | |||
Gross Profit | -22.01% | 32.06% | |||
SG&A Expenses | -35.73% | 70.68% | |||
Depreciation & Amortization | -- | -- | |||
Other Operating Expenses | -- | -- | |||
Total Operating Expenses | -9.17% | 7.16% | |||
Operating Income | 160.79% | -178.16% | |||
Income Before Tax | 24.95% | -81.56% | |||
Income Tax Expenses | -- | -- | |||
Earnings from Continuing Operations | 24.95% | -81.56% | |||
Earnings from Discontinued Operations | -- | -- | |||
Extraordinary Item & Accounting Change | -- | -- | |||
Minority Interest in Earnings | -- | -- | |||
Net Income | 24.95% | -81.56% | |||
EBIT | 160.79% | -178.16% | |||
EBITDA | 116.36% | -60.81% | |||
EPS Basic | 30.56% | -44.00% | |||
Normalized Basic EPS | 33.33% | -60.00% | |||
EPS Diluted | 30.56% | -44.00% | |||
Normalized Diluted EPS | 33.33% | -60.00% | |||
Average Basic Shares Outstanding | 8.80% | 25.06% | |||
Average Diluted Shares Outstanding | 8.86% | 25.20% | |||
Dividend Per Share | -- | -- | |||
Payout Ratio | -- | -- |